Chemistry: molecular biology and microbiology – Vector – per se
Reexamination Certificate
2006-01-31
2006-01-31
Li, Q. Janice (Department: 1632)
Chemistry: molecular biology and microbiology
Vector, per se
C424S093100, C424S093200, C424S093600, C435S235100, C435S456000, C435S325000, C435S455000
Reexamination Certificate
active
06991935
ABSTRACT:
The invention provides adenoviral vectors (preferably replication competent) comprising both an E3 sequence and at least one adenoviral gene under transcriptional control of a target cell-specific transcriptional response element. These vectors display significantly improved cytotoxicity, which is especially useful in the cancer context, in which selective destruction of target cells is desirable. The invention further provides host cells comprising the vectors. The invention further provides methods of using the adenoviral vectors.
REFERENCES:
patent: 5585362 (1996-12-01), Wilson et al.
patent: 5648478 (1997-07-01), Henderson
patent: 5698443 (1997-12-01), Henderson et al.
patent: 5830686 (1998-11-01), Henderson
patent: 5871726 (1999-02-01), Henderson et al.
patent: 5998205 (1999-12-01), Hallenbeck et al.
patent: 6020191 (2000-02-01), Scaria et al.
patent: 6057299 (2000-05-01), Henderson
patent: 6197293 (2001-03-01), Henderson et al.
patent: 6254862 (2001-07-01), Little et al.
patent: 6495130 (2002-12-01), Henderson et al.
patent: 2205078 (1997-11-01), None
patent: 0 808 905 (1997-11-01), None
patent: 0 808 905 (1997-11-01), None
patent: WO 95/11984 (1995-05-01), None
patent: WO 95/11984 (1995-05-01), None
patent: WO 95/14100 (1995-05-01), None
patent: WO 95/14100 (1995-05-01), None
patent: WO 95/19434 (1995-07-01), None
patent: WO 96/17053 (1996-06-01), None
patent: WO 96/34969 (1996-11-01), None
patent: WO 97/01358 (1997-01-01), None
patent: WO 98/04132 (1998-02-01), None
patent: WO 98/05797 (1998-02-01), None
patent: WO 98/37189 (1998-08-01), None
patent: WO 98/39464 (1998-09-01), None
patent: WO 98/39464 (1998-09-01), None
patent: WO 98/39465 (1998-09-01), None
patent: WO 98/39465 (1998-09-01), None
patent: WO 98/39466 (1998-09-01), None
patent: WO 98/39466 (1998-09-01), None
patent: WO 98/39467 (1998-09-01), None
patent: WO 98/39467 (1998-09-01), None
patent: WO 99/06576 (1999-02-01), None
patent: WO 99/25860 (1999-05-01), None
patent: WO 00/15820 (2000-03-01), None
patent: WO 00/20041 (2000-04-01), None
Ilan et al, PNAS 1997;94:2587-92.
Abe, M. and Kufe, D. (1990) “Transcriptional regulation of DF3 gene expression in human MCF-7 breast carcinoma”J. Cell. Physiol.143:226-231.
Abe, M. and Kufe, D. (1993) “Characterization of cis-acting elements regulating transcription of the human DF3 breast carcinoma-associated antigen (MUC1) gene”Proc. Natl. Acad. Sci. USA90:282-286.
Amberg et al. (1997) “Fiber genes of adenoviruses with tropism for the eye and the genital tract”Virology227:239-244.
Ausubel et al., Eds. (1987) in: Current Protocols in Molecular Biology, Suppl. 30, Section 7.7.18, Table 7.7.1.
Bailey et al. (1993) “Enteric adenovirus type 40: expression of E1B proteins in vitro and in vivo”Virology193:631-641.
Bailey et al. (1994) “Cell type specific regulation of expression from the Ad40 E1b promoter in recombinant Ad5/Ad40 viruses”Virology202:695-706.
Behringer et al. (1988) “Dwarf mice produced by genetic ablation of growth hormone-expressing cells”Genes Dev.2:453-461.
Bischoff et al. (1996) “An adenovirus mutant that replicates selectively in p53-deficient human tumor cells”Science274:373-376.
Bridge et al. (1989) “Redundant control of adenovirus late gene expression by early region 4”J. Virol.63(2):631-638.
Bunn et al. (1996) “Oxygen sensing and molecular adaptation to hypoxia”Physiol. Rev.76(3):839-885.
Bursch et al. (1990) “Determination of the length of the histological stages of apoptosis in normal liver and in altered hepatic foot of rats”Carcinogenesis11(5):847-853.
Bursch et al. (1992) “Cell death by apoptosis and it protective role against disease”Trends Pharm. Sci.13:245-251.
Cannio et al. (1991) “A cell-type specific and enhancer-dependent silencer in the regulation of the expression of the human urokinase plasminogen activator gene”Nucl. Acids Res.19:2303-2308.
Chengalvata et al. (1997) “Replication and immunogenicity of Ad7-, Ad4-, and Ad5-hepatitis B virus surface antigen recombinants, with or without a portion of E3 region, in chimpanzees”Vaccine15:335-339.
Dachs et al. (1997) “Targeting gene expression to hypoxic tumor cells”Nat. Med.3:515-520.
Dachs, G. and Stratford, I. (1996) “The molecular response of mammalian cells to hypoxia and the potential for exploitation in cancer therapy”Br. J. Cancer Suppl.74:S126-S132.
Dai, J. and Burnstein, K. (1996) “Two androgen response elements in the androgen receptor coding region are required for cell-specific up-regulation of receptor messenger RNA”Mol. Endocrinol.10:1582-1594.
Dodd et al. (1983) “Characterization and cloning of rat dorsal prostate mRNAs. Androgen regulation of rwo closely related abundant mRNAs”J. Biol. Chem.258:10731-10737.
Elsing et al. (1998) “The adenovirus E3/10.4K-14.5K proteins down-modulate the apoptosis receptor Fas/Apo-1 by inducing its internalization”Proc. Natl. Acad. Sci. USA95:10072-10077.
Firth et al. (1994) “Oxygen-regulated control elements in the phosphoglycerate kinase 1 and lactate dehydrogenase A genes: similarities with the erythropoietin 3′ enhancer”Proc. Natl. Acad. Sci. USA91:6496-6500.
Flint, S.J. (1982) “Expression of adenoviral genetic information in productively infected cells”Biochem. Biophys. Acta651:175-208.
Flint, S.J. (1986) “Regulation of adenovirus mRNA formation”Adv. Virus Res.31:169-228.
Folkman, J. (1990) “What is the evidence that tumors are angiogenesis dependent?”J. Natl. Can. Inst.82:4-6.
Foster et al. (1997) “Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model”Cancer Res.57:3325-3330.
Frankel et al. (1989) “Selection and Characterization of ricin toxin A-chain mutations inSaccharomyces cerevisiae” Mol. Cell. Biol.9:415-420.
Ginsberg, H.S. (1996) “The ups and downs of adenovirus vectors”Bull. NY Acad. Med. Summer73(1):53-58.
Girling et al. (1989) “A core protein epitope of the polymorphic epithelial mucin detected by the monoclonal antibody SM-3 is selectively exposed in a range of primary carcinomas”Int. J. Cancer43:1072-1076.
Grand, R.J. (1987) “The structure and functions of the adenovirus early region 1 proteins”Biochem. J.241:25-38.
Greenberg et al. (1994) “The rat probasin gene promoter directs hormonally and developmentally regulated expression of a heterologous gene specifically to the prostate in transgenic mice”Mol. Endocrinol.8:230-239.
Greenberg et al. (1995) “Prostate cancer in a transgenic mouse”Proc. Natl. Acad. Sci. USA92:3439-3443.
Grooteclaes et al. (1994) “The 6-kilobase c-erbB2 promoter contains positive and negative regulatory elements functional in human mammary cell lines”Cancer Res.54:4193-4199.
Guillemin, K and Krasnow, M. (1997) “The hypoxic response: huffing and HIFing”Cell89:9-12.
Hallahan et al. (1995) “Spatial and temporal control of gene therapy using ionizing radiation”Nat. Med.1:786-791.
Hilkens, J. (1988) “Biochemistry and function of mucins in malignant disease”Cancer Rev.11-12:25-54.
Horwitz et al. (1995) “Model systems for studying the effects of adenovirus E3 genes on virulence in vivo”Curr. Topics Microbiol. Immunol.199(Pt 1):195-211.
Hudson et al. (1990) “Studies and inducible regulation of the human c-erb B2
eu promoter”J. Biol. Chem.265:4389-4393.
Ido et al. (1995) “Gene therapy for hepatoma cells using a retrovirus vector carrying herpes simplex virus thymidine kinase gene under the control of human alpha-fetoprotein gene promoter”Cancer Res.55:3105-3109.
Ilan et al. (1997) “Insertion of the adenoviral E3 region into a recombinant viral vector prevents antiviral humoral and cellular immune responses and permits long-term gene
Henderson Daniel R.
Yu De-Chao
Cell Genesys Inc.
DLA Piper Rudnick Gray Cary US LLP
Li Q. Janice
LandOfFree
Target cell-specific adenoviral vectors containing E3 and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Target cell-specific adenoviral vectors containing E3 and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Target cell-specific adenoviral vectors containing E3 and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3563461